

# CONTENTS

*List of figures*

*List of tables*

*Abbreviations*

*Preface*

---

| <b>Chapters</b>  | <b>Page No.</b> |
|--|-----------------|
| <b>1. Introduction.....</b>                                    | <b>1-12</b>     |
| <b>2. Literature Review.....</b>                               | <b>13-32</b>    |
| 2.1. Treatment of lung cancer.....                             | 13              |
| 2.1.1. Surgery.....  | 13              |
| 2.1.2. Radiation Therapy.....                                  | 13              |
| 2.1.3. Photodynamic Therapy (PDT).....                         | 14              |
| 2.1.4. Chemotherapy.....                                       | 14              |
| 2.2. Docetaxel (DXL).....                                      | 15              |
| 2.2.1. Chemical structure of DXL.....                          | 15              |
| 2.2.2. IUPAC name.....   | 15              |
| 2.2.3. Solubility.....   | 16              |
| 2.2.4. Molecular weight.....                                   | 16              |
| 2.2.5. Molecular formula.....                                  | 16              |
| 2.2.6. Pharmacokinetics.....                                   | 16              |
| 2.2.7. Mechanism of Action.....                                | 16              |
| 2.3 Cabazitaxel (CZT).....                                     | 17              |
| 2.3.1. Chemical structure of CZT.....                          | 17              |
| 2.3.2 IUPAC name.....  | 17              |
| 2.3.3. Solubility.....   | 17              |
| 2.3.4. Molecular weight.....                                   | 17              |
| 2.3.5. Molecular formula.....                                  | 17              |
| 2.3.6. Pharmacokinetics.....                                   | 17              |
| 2.3.7. Mechanism of Action.....                                | 18              |
| 2.4. Targeted therapy of lung cancer.....                      | 18              |
| 2.4.1. EGFR inhibitors.....                                    | 19              |
| 2.4.1.1. Cetuximab (CTXmab).....                               | 19              |
| 2.5. Nanomedicine in the treatment of NSCLC.....               | 20              |
| 2.6. Limitation in single targeted nanomedicines.....          | 21              |
| 2.7. Dual-receptor targeted nanomedicines for lung cancer..... | 22              |
| 2.8. Chitosan as polymer material for nanomedicine.....        | 26              |
| 2.8.1. Chemical structure of CS.....                           | 26              |
| 2.8.2. Molecular formula.....                                  | 26              |
| 2.8.3. Molecular weight.....                                   | 26              |

|  |              |
|--|--------------|
| 2.8.4. Chitosan-alginate (CSA) based nanoparticles.....  | 27           |
| 2.9. Methods of preparation of polymeric nanoparticles.....                                      | 27           |
| 2.9.1. Solvent evaporation.....  | 28           |
| 2.9.2. Dialysis method.....  | 28           |
| 2.9.3. Coacervation/precipitation.....   | 28           |
| 2.9.4. Emulsion-droplet coalescence.....   | 29           |
| 2.9.5. Reverse micellization.....  | 29           |
| 2.9.6. Ionotropic gelation.....  | 30           |
| 2.10. D- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate (TPGS).....                     | 30           |
| 2.10.1. Chemical structure of TPGS.....  | 31           |
| 2.10.2. IUPAC name.....  | 31           |
| 2.10.3. Molecular formula.....   | 31           |
| 2.10.4. Molecular weight.....  | 31           |
| 2.11. Chemical induced lung cancer mice model.....   | 31           |
| <b>3. Dual-receptor targeted chitosan nanoparticles of docetaxel</b>                             | <b>33-78</b> |
| 3.1. Objective.....  | 33           |
| 3.2. Plan of study.....  | 33           |
| 3.3. Material.....   | 33           |
| 3.4. Methods.....  | 34           |
| 3.4.1. Synthesis of chitosan-folate (CS-F) conjugate.....  | 34           |
| 3.4.2. Characterization of CS-F.....   | 35           |
| 3.4.2.1. Degree of folic acid substitution.....  | 35           |
| 3.4.3. Preparation of acid functionalized TPGS (TPGS-COOH).....                                  | 36           |
| 3.4.4. Characterization of TPGS-COOH.....  | 36           |
| 3.4.5. Preparation of DXL/C6 loaded dual-receptor targeted chitosan nanoparticles (CS NPs) ..... | 36           |
| 3.4.6. Nanoparticles characterization.....   | 39           |
| 3.4.6.1. Particle size, polydispersity and surface charge.....                                   | 39           |
| 3.4.6.2. Transmission electron microscopy (TEM) analysis.....                                    | 39           |
| 3.4.6.3. Scanning electron microscopy (SEM) analysis.....  | 40           |
| 3.4.6.4. Atomic force microscopy (AFM)analysis.....  | 40           |
| 3.4.6.5. X-ray photoelectron spectroscopy (XPS) analysis.....                                    | 40           |
| 3.4.6.6. Degree of conjugation.....  | 40           |
| 3.4.6.6.1. Folic acid content.....   | 40           |
| 3.4.6.6.2. CTXmab content.....   | 41           |
| 3.4.6.7. Entrapment efficiency.....  | 41           |
| 3.4.6.8. X-ray diffraction (XRD) analysis.....   | 42           |
| 3.4.7. <i>In-vitro</i> evaluation.....   | 42           |
| 3.4.7.1. <i>In-vitro</i> release study.....  | 42           |
| 3.4.7.2. <i>In-vitro</i> cellular uptake study.....  | 43           |
| 3.4.7.3. <i>In-vitro</i> cytotoxicity study.....   | 44           |
| 3.4.8. <i>In-vivo</i> characterization.....  | 44           |
| 3.4.8.1. Pharmacokinetic study.....  | 44           |
| 3.4.8.2. Histopathology study.....   | 45           |
| 3.4.8.3. Tumour regression and survival analysis.....  | 47           |
| 3.5. Results and discussion.....   | 47           |
| 3.5.1. Characterization of CS-F.....   | 47           |

|   |               |
|---|---------------|
| 3.5.1.1. FTIR analysis.....   | 47            |
| 3.5.1.2. Nuclear magnetic resonance spectroscopy.....                               | 48            |
| 3.5.1.3. Mass spectroscopy.....   | 59            |
| 3.5.1.4. Degree of folic acid substitution.....                                     | 51            |
| 3.5.2. Characterization of TPGS-COOH.....   | 51            |
| 3.5.2.1. FTIR analysis.....   | 51            |
| 3.5.2.2. Nuclear magnetic resonance.....  | 52            |
| 3.5.2.3. Mass spectroscopy.....   | 56            |
| 3.5.3. Particle size distribution and surface charge.....                           | 57            |
| 3.5.4. TEM analysis.....  | 58            |
| 3.5.5. SEM analysis.....  | 58            |
| 3.5.6. AFM analysis.....  | 59            |
| 3.5.7. Drug entrapment efficiency of nanoparticles.....                             | 60            |
| 3.5.8. XRD analysis.....  | 61            |
| 3.5.9. XPS analysis.....  | 62            |
| 3.5.10. Degree of conjugation.....  | 65            |
| 3.5.10.1. Folic acid content.....   | 65            |
| 3.5.10.2. CTXmab content.....   | 65            |
| 3.5.11. <i>In-vitro</i> evaluation.....   | 65            |
| 3.5.11.1 <i>In-vitro</i> drug release study.....                                    | 65            |
| 3.5.11.2. <i>In-vitro</i> cellular uptake study.....                                | 67            |
| 3.5.11.3. <i>In-vitro</i> cytotoxicity studies.....                                 | 67            |
| 3.5.12. <i>In-vivo</i> characterization.....  | 71            |
| 3.5.12.1. Pharmacokinetic study.....  | 72            |
| 3.5.12.2. Histopathological analysis.....   | 73            |
| 3.5.12.3. Tumour regression and survival analysis.....                              | 76            |
| 3.6. Conclusion.....  |               |
| <b>4. Dual-receptor targeted chitosan-alginate nanoparticles of cabazitaxel</b>     | <b>79-110</b> |
| 4.1. Objective.....   | 79            |
| 4.2. Plan of study.....   | 79            |
| 4.3. Material.....  | 79            |
| 4.4. Methods.....   | 79            |
| 4.4.1. Optimization of the mixture of sodium-TPP and sodium-alginate.....           | 79            |
| 4.4.2. Preparation of CZT/C6 loaded chitosan-alginate nanoparticles (CSA-NPs) ..... | 79            |
| 4.4.2. Characterization of nanoparticles.....                                       | 83            |
| 4.4.2.1. Surface charge, particle size, and polydispersity.....                     | 83            |
| 4.4.2.2. Electron microscopic evaluation of CSA-NPs .....                           | 83            |
| 4.4.2.2.1. TEM analysis.....  | 83            |
| 4.4.2.2.2. SEM analysis.....  | 83            |
| 4.4.2.2.3. AFM analysis.....  | 79            |
| 4.4.2.3. Surface chemistry.....   | 84            |
| 4.4.2.4. Degree of conjugation.....   | 84            |
| 4.4.2.4.1. Folic acid content.....  | 84            |
| 4.4.2.4.2. CTXmab content.....  | 85            |
| 4.4.2.5. Determination of entrapment efficiency.....                                | 85            |

|   |                |
|---|----------------|
| 4.4.2.6. XRD analysis.....                                | 85             |
| 4.4.2.7. <i>In-vitro</i> evaluation.....                  | 86             |
| 4.4.2.7.1. <i>In-vitro</i> release study.....             | 86             |
| 4.4.2.7.2. <i>In-vitro</i> cellular uptake study.....     | 87             |
| 4.4.2.7.3. <i>In-vitro</i> cytotoxicity assay.....        | 88             |
| 4.4.2.8. <i>In-vivo</i> evaluation.....                   | 88             |
| 4.4.2.8.1. Pharmacokinetic analysis.....                  | 89             |
| 4.4.2.8.2. Histopathology study.....                      | 89             |
| 4.4.2.8.3. Tumour regression and survival analysis.....   | 90             |
| 4.5. Results and discussion.....                          | 91             |
| 4.5.1. Particle size distribution and surface charge..... | 91             |
| 4.5.2. Electron microscopic evaluation of CSA-NPs .....   | 92             |
| 4.5.2.1. TEM analysis.....                                | 92             |
| 4.5.2.2. SEM analysis.....                                | 93             |
| 4.5.2.3. AFM analysis.....                                | 93             |
| 4.5.3. Surface chemistry.....                             | 94             |
| 4.5.4. Determination of entrapment efficiency.....        | 94             |
| 4.5.5. Degree of conjugation.....                         | 94             |
| 4.5.5.1. Folic acid.....                                  | 94             |
| 4.5.5.2. CTXmab.....                                      | 96             |
| 4.5.6. XRD analysis.....                                  | 96             |
| 4.5.7. <i>In-vitro</i> evaluation.....                    | 97             |
| 4.5.7.1 <i>In-vitro</i> release study.....                | 97             |
| 4.5.7.2. <i>In-vitro</i> cellular uptake study.....       | 101            |
| 4.5.7.3. <i>In-vitro</i> cytotoxicity studies.....        | 101            |
| 4.5.8. <i>In-vivo</i> evaluation.....                     | 102            |
| 4.5.8.1. Pharmacokinetic study.....                       | 102            |
| 4.5.8.2. Histopathological analysis.....                  | 105            |
| 4.5.8.2. Tumour regression and survival analysis.....     | 105            |
| 4.6. Conclusion.....                                      | 108            |
| <b>5. Summary and conclusions.....</b>                    | <b>111-116</b> |
| <b>6. References.....</b>                                 | <b>117-140</b> |
| <b>7. Publications.....</b>                               | <b>141-142</b> |
| <b>8. Curriculum Vitae.....</b>                           | <b>143-147</b> |